Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes time to progression compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes progression‐free survival compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes treatment‐related death compared with 5‐FU‐containing regimens (very low certainty).
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
Oxaliplatin may leads to lower overall Survival compared with the same regimen including cisplatin (low certainty).
Oxaliplatin probably leads to higher tumour response compared with the same regimen including cisplatin (moderate certainty).
Oxaliplatin showed no clear difference in progression‐free survival compared with the same regimen including cisplatin (low certainty).
Oxaliplatin showed no clear difference in treatment‐related death compared with the same regimen including cisplatin (low certainty).
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
It is very uncertain whether oxaliplatin changes treatment discontinuation due to toxicity compared with the same regimen including cisplatin (very low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).